🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "major milestone" in the battle against increasingly resistant strains of the pathogen, according to scientists.

A Worldwide Health Concern

The sexually transmitted infection are increasing globally, with figures suggesting in excess of 82 million new cases per year. Especially elevated rates are observed in the African continent and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune advancement in the face of rising global incidence, increasing antimicrobial resistance and the extremely scarce available drugs currently available.”

Health officials are deeply concerned about the increase in treatment-resistant strains. The WHO has designated it as a "critical concern". Ongoing monitoring revealed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Receive Clearance

One new antibiotic, marketed under the name a brand name, was cleared by the American regulatory agency in mid-December for treating gonorrhoea. This STI can lead to major issues, including infertility. Scientists hope that focused deployment of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, gained clearance in the same week. This treatment, which is additionally indicated for urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This authorization marks a significant shift in the management of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Research Study Data and Worldwide Availability

According to data published in a major medical journal, the new drug successfully treated over nine in ten of cases of the STI. This puts it on an comparable level with the typical regimen, which involves two antibiotics. The research enrolled over 900 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the rights to license and sell the drug in numerous developing nations.

Clinicians on the front lines have shared positive views. The availability of a one-pill regimen like this is hailed as a "critical tool" for public health efforts. This is viewed as vital to lessen the impact of the disease for individuals and to prevent the spread of untreatable gonorrhoea around the world.